Topic

UnitedHealthcare (UnitedHealth Group)

A collection of 1322 issues

Lowering Out-of-Pocket Costs for Enhertu with UnitedHealthcare in North Carolina: Copay Cards, Tiering Appeals, and Financial Assistance

Answer Box: Enhertu (fam-trastuzumab deruxtecan-nxki) costs $150,000+ annually but UnitedHealthcare commercial patients can reduce out-of-pocket to $0 drug cost plus $100/infusion using the ENHERTU4U copay program. Submit prior authorization via UnitedHealthcare Provider Portal with HER2-positive pathology results and prior therapy documentation. If denied, appeal internally within 180 days,
6 min read

How to Get Givlaari (Givosiran) Covered by UnitedHealthcare in Washington: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Givlaari Covered by UnitedHealthcare in Washington Givlaari (givosiran) requires prior authorization from UnitedHealthcare OptumRx, with potential step therapy requirements. Washington state law (RCW 48.43.420) provides strong protections for step therapy exceptions when medically necessary. First step: Have your specialist submit a prior authorization request with
6 min read

How to Get Amvuttra (Vutrisiran) Covered by UnitedHealthcare in Washington: Complete Guide to Prior Authorization, Appeals, and External Review

Answer Box: Getting Amvuttra Covered by UnitedHealthcare in Washington UnitedHealthcare requires prior authorization for Amvuttra (vutrisiran) in Washington. Submit documentation including TTR genetic testing, specialist evaluation, and baseline outcomes via OptumRx PreCheck Prior Authorization or call 1-800-711-4555. If denied, appeal within 65 days internally, then request external review through Washington&
6 min read

Work With Your Doctor to Get Opdivo (nivolumab) Approved by UnitedHealthcare in Ohio: Complete Provider Collaboration Guide

Answer Box: Your Path to Opdivo Approval Getting Opdivo (nivolumab) covered by UnitedHealthcare in Ohio requires prior authorization with specific biomarker testing and clinical documentation. Work with your oncologist to submit evidence through UnitedHealthcare's provider portal, request peer-to-peer review if denied (~85% overturn rate), and use Ohio'
6 min read

Myths vs. Facts: Getting Uplizna (Inebilizumab) Covered by UnitedHealthcare in California

Quick Answer: UnitedHealthcare requires prior authorization for Uplizna (inebilizumab) in California with specific documentation: AQP4-positive NMOSD diagnosis, neurologist prescription, HBV screening, and often step therapy with eculizumab first. If denied, file internal appeal within 180 days, then California's Independent Medical Review (IMR) through DMHC. Start by gathering AQP4-IgG
5 min read

How to Get Stelara (Ustekinumab) Covered by UnitedHealthcare in Washington: Complete Guide to Prior Authorization, Appeals, and Medical Necessity Letters

Answer Box: Your Path to Stelara Coverage in Washington UnitedHealthcare requires prior authorization for brand Stelara (ustekinumab) with step therapy through biosimilars first. In Washington, if denied, you have 180 days for internal appeals plus external review through an Independent Review Organization. Start today: Have your doctor submit a medical
6 min read

Get Waylivra (Volanesorsen) Covered by UnitedHealthcare in Florida: Complete Guide to Forms, Appeals, and Approval

Quick Answer: Getting Waylivra Covered in Florida Waylivra (volanesorsen) requires prior authorization through UnitedHealthcare's OptumRx system in Florida. Submit PA requests via the UnitedHealthcare Provider Portal with confirmed FCS diagnosis, triglyceride levels >880 mg/dL, and prior therapy documentation. If denied, file internal appeals within 180 days,
6 min read

How to Get Rezlidhia (olutasidenib) Covered by UnitedHealthcare in Pennsylvania: Prior Authorization, Appeals, and Renewal Guide

Answer Box: Getting Rezlidhia (olutasidenib) covered by UnitedHealthcare in Pennsylvania requires prior authorization with IDH1 mutation testing, documented AML diagnosis, and prior therapy history. If denied, you have 180 days for internal appeals, then 4 months for Pennsylvania's external review (50% overturn rate). Start by having your oncologist
6 min read